Rocket Pharmaceuticals (RCKT) Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for Treatment of Danon Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. SYNA
2. ON
3. SPY
4. MU
5. AAPL
6. VEON
7. SPCX
8. ABBV
9. DRI
10. ACAD

Go back to Rocket Pharmaceuticals (RCKT) Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for Treatment of Danon Disease

Rocket Pharmaceuticals (RCKT) Prices 4.64M Share Upsized Common Offering at $56/Sh

December 10, 2020 6:00 AM EST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the pricing of an upsized underwritten public offering of 4,642,858 shares of its common stock at a public offering price of... More

Rocket Pharmaceuticals (RCKT) Announces $175M Proposed Public Offering of Common Stock

December 9, 2020 7:51 AM EST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has commenced an underwritten public offering of $175 million of shares of its common stock. Rocket also intends to grant the underwriters a... More